The athymic nude mouse is often used to grow tumors for in vivo oncology research, including the identification of anticancer drugs, whereas wild-type mice are usually used to assess the pharmacokinetics (PK) of new chemical entities. The relationship between PK and pharmacodynamics (PD) provides useful mechanistic information and helps guide of the clinical regimen. The aim of this study was to assess whether the inoculation of human hepatocellular carcinoma cells (PLC/PRF/5) into athymic nude mice alters the expression of genes encoding the drug-metabolizing enzymes and transporters in host liver. The livers from nontumor-and tumor-bearing mice were initially subjected to drug metabolism gene microarray analysis. Microarray analysis indicated that tumor inoculation had little effect on drug metabolism-related genes, including several cytochrome P450s: Cyp1a, Cyp2b, and Cyp3a. This result was further confirmed by reverse transcription-polymerase chain reaction (RT-PCR). However, immunoreactive proteins of Cyp1a, Cyp2b, and Cyp3a were suppressed by tumor inoculation. RT-PCR and Western immunoblotting analysis showed that the inducibility of Cyp1a, Cyp2b, and Cyp3a by 3-methylcholanthrene, phenobarbital, and dexamethasone, respectively, was similar between nontumor-and tumor-bearing mice. These results suggest that inoculation of human tumor cells into athymic nude mice suppresses the expression of certain drug-metabolizing enzymes, which may alter the PK and PD of antitumor drugs.
Inoculation of human cancer cells into the athymic nude mouse is a very useful in vivo xenograft system to evaluate the effectiveness of anticancer drugs in drug discovery and development. Athymic mice are born without a thymus gland and cannot generate mature T lymphocytes. This immunodeficiency allows a variety of human cancer cells to be inoculated into mice and develop into tumors without rejection (Rolstad, 2001) . However, although athymic mice having the nude mutation are T cell-deficient, they have a compensatory increase in innate immunity, most notably increased natural killer cell and tumoricidal macrophage activities (Talmadge et al., 2007) . In the xenograft model, the host is an animal and tumor is a human-derived cell line. Tumor-host interactions have been reported to differ according to the location of the tumor and can alter the pharmacodynamic effects of a drug candidate. For instance, Teicher et al. (1990) reported alterations in the pharmacokinetics (PK) of alkylating agents due to the tumor-host response. The tumor implant site also influences tumor growth kinetics and behavior (Malavé et al., 1979; Hill and Denekamp, 1982) .
Parallel to in vivo screening for identifying pharmacologically effective antitumor compounds, in vivo studies are performed to evaluate the safety and PK properties of drug candidates. In drug discovery and development, PK is usually evaluated in normal animals to assess the metabolism, disposition, and systemic exposure for new chemical entities. The relationship between PK and pharmacodynamics (PD) provides useful information on the mechanism of action of the drug candidate and can be used to estimate the clinical dosing regimen (Simeoni et al., 2004; Luo et al., 2005a,b) . However, it is not known whether the PK data from normal mice are applicable to athymic nude mice or whether the expression and regulation of drug-metabolizing enzymes (DMEs) and transporters in athymic nude mice are altered after tumor inoculation. Therefore, information on the effects of tumor inoculation on the disposition of new chemical entities in athymic nude mice would be extremely useful. Regarding strain differences, no difference in enzymatic activities and metabolite formation between CD-1 and athymic nude mice has been reported (Martignoni et al., 2005) , although these authors did not investigate the effect of tumor inoculation on host liver.
The liver is the primary site for drug metabolism and contains metabolizing enzymes and transporters of drugs and other xenobiotics. The acronym ADME stands for absorption, distribution, metabolism, and excretion and describes the four main processes of drug disposition. The process of drug disposition can be divided into three phases: phase I, oxidation by enzymes; phase II, conjugation by enzymes; and phase III, elimination by transporters (Nakata et al., 2006; Huang et al., 2008) . The phase I system involves cytochrome P450 (P450) and flavin mixed-function oxidase, microsomal monooxygenases that catalyze the oxidation of numerous xenobiotics. Phase II enzymes catalyze the conjugation of certain drugs and a large number of phase I metabolites. Transporters in the phase III system eliminate phase I/II metabolites from cells. In addition to phase I, II, and III proteins, several nuclear receptors (xenosensors) are critically involved in the induction (up-regulation) or suppression (down-regulation) of various enzymes and transporters (Xu et al., 2005; Lin, 2006; Hewitt et al., 2007) . The nuclear receptors are expressed in many tissues such as intestine, liver, kidney, and brain and also play an indirect but key role in drug metabolism and disposition (Choudhary et al., 2003) . The major xenosensors that regulate the expression of DME and transporters are the arylhydrocarbon receptor (AhR), constitutive androstane receptor (CAR), and pregnane X receptor (PXR). CYP1 genes can be induced by AhR, which heterodimerizes with the AhR nuclear translocator and responds to many polycyclic aromatic hydrocarbons. The steroid family of orphan nuclear receptors, CAR and PXR, both heterodimerize with the retinoid X receptor and have been shown to transcriptionally activate the promoters of the CYP2B and CYP3A genes.
The aim of this study was to characterize the effect of inoculation of human hepatocellular carcinoma cells (PLC/PRF/5) into athymic nude mice on the expression of genes encoding several DME and transporters in the host liver.
volume, after which they were given intraperitoneal injections of corn oil (10 ml/kg, vehicle control), MC (100 mg/kg), PB (100 mg/kg), Dex (100 mg/kg), or PTX (40 mg/kg) once daily for four consecutive days. The inducers MC, PB, and Dex were all suspended in corn oil, whereas PTX was dissolved in Cremophor solvent (a clinically used formulation), which comprised Cremophor EL (5%, v/v), ethanol (5%, v/v), and 5% glucose (90%, v/v). The dose of PTX, a Cyp3a inducer, was selected based on studies by Nallani et al. (2003) . The treatment groups consisted of vehicle control groups in nontumor-and tumor-bearing mice (n ϭ 3 each), and MC-, PB-, Dex-, and PTX-treated groups in nontumor-and tumor-bearing mice (n ϭ 4 each). Livers were harvested 24 h after the last treatment, frozen in liquid nitrogen, and stored at Ϫ80°C until processed and analyzed.
RNA Extraction. Liver was homogenized in TRIzol reagent (1 ml of solution per 10 mg of liver tissue; Invitrogen) with a Physcotron homogenizer (Microtec., Ltd., Chiba, Japan), followed by chloroform extraction. Total RNA was purified with an RNeasy Mini Kit (QIAGEN, Tokyo, Japan). The concentration of purified RNA was measured with a NanoDrop spectrophotometer (SCRUM Inc., Tokyo, Japan), and its quality was assessed with a 2100 Bioanalyzer (Agilent Technologies, Tokyo, Japan).
Reverse Transcription Reaction. cDNA was synthesized from 2 g of total RNA with a High Capacity cDNA Transcription Kit (Applied Biosystems, Tokyo, Japan). In brief, 2 l of 10ϫ reverse transcription buffer, 0.8 l of 25ϫ dNTPs, 2 l of random primers, 1 l of Multiscribe reverse transcriptase (50 U/l), and 0.8 l of nuclease-free water were combined in a 96-well plate. Reverse transcription was performed on a GeneAmp PCR 9700 system (Applied Biosystems) for 10 min at 25°C, followed by 120 min at 37°C, and terminated at 95°C for 10 min.
Quantitative Real-Time PCR. TaqMan and SYBR Green protocols were used to amplify cDNAs of each mRNA of interest by real-time quantitative PCR using a 7900HT system (Applied Biosystems). The primers and TaqMan probes designed for this study were synthesized by Sigma Genosys (Hokkaido, Japan) and are listed in Table 1 . Primer and probe sets for Cyp2b9 (Mm00657910_m1), Cyp2b10 (Mm00657910_m1), Cyp2b13 (Mm00771172_g1), Cyp3a41 (Mm00776855_mH), and GAPDH (4308313) were from Applied Biosystems.
PCR amplifications were carried out in 12-l reaction volumes consisting of 5 l of cDNA templates, 6 l of PCR Master Mix, 200 nM forward primer, and 200 nM reverse primer in a 384-well plate. In TaqMan assays, a 200 nM TaqMan probe was also added to the above reaction mixture. Reactions were heated at 95°C for 10 min, followed by 50 cycles of amplification consisting of denaturation at 94°C for 15 s, and annealing and extension at 60°C for 1 min. The mRNA levels of the dilution series (from 0.0167 to 167 ng/l) of a standard RNA sample were obtained from mouse liver total RNA (Takara Bio, Shiga, Japan) and the level of each mRNA of interest was normalized to the level of GAPDH mRNA. Results were then expressed as -fold change over control samples. Microarray. A total of 45 RNA samples (10 g each) were analyzed by GeneSQUARE Multiple Assay DNA Microarray Drug Metabolism Gene Expression for Mouse (MAPM-01; Kurabo Industries Ltd., Osaka, Japan). Alexa Fluor 555-labeled cDNA was prepared from total RNA from mouse liver through cDNA synthesis and in vitro transcription was performed using a GeneSQUARE cDNA Direct Labeling System (MADL-1; Kurabo Industries Ltd.) according to the manufacturer's protocol. Labeled cDNA was purified with a MinElute PCR Purification Kit (QIAGEN) and added to hybridization buffer [5ϫ SSC, pH 7.0, 4ϫ Denhardt's solution, 1 g of salmon sperm DNA, and 0.5% (w/v) SDS]. Prehybridization was carried out in 4ϫ SSC, 1% BSA, and 0.5% SDS solution at 42°C for 45 min in a water bath. Hybridization was performed within 1 h of the prehybridization in a final volume of 8 l/well by GeneSQUARE Multiple Assay DNA Microarray Drug Metabolism Gene Expression for Mouse (Kurabo Industries Ltd.) in a plastic enclosure at 65°C. After hybridization for 10 to 16 h, hybridized slides were washed by the following steps: 1) immersion in 1ϫ SSC and 0.1% SDS solution for 5 min, 2) immersion in 0.2ϫ SSC and 0.1% SDS for 5 min, (3) immersion in 0.2ϫ SSC and 0.1% SDS at 55°C for 5 min, 4) rocking in 0.2ϫ SSC, and 5) immersion in 0.05% SSC for 2 min. After they were dried under nitrogen, the slides were scanned with a GenePix 4000B scanner with GenePix Pro 6.0.1.27 (Intermedical Co., Ltd., Aichi, Japan) at Kurabo Industries Ltd. Fluorescence intensities of scanned images were quantified, corrected for background, and normalized by the intensity of GAPDH.
Microarray Data Analysis. Signals were considered to be measurable (present) or unmeasurable (absent) when the intensity of each spot was above FIG. 1. Heatmap of basal expression of ADME genes in nontumor-and tumor-bearing athymic nude mice. Gene expression in tumor-bearing mouse liver was compared with that in nontumor-bearing mouse liver. Each treatment group has three replicates, and the means were used to calculate -fold differences. The heatmap is scaled to approximately 3-fold up (red) or down (green). dmd.aspetjournals.org or below threshold. The threshold was set to either the higher value in 2-fold median intensity of six negative controls or an average value of background intensities. mRNAs judged to be absent from all samples were not used in this analysis. When the mRNA was detectable in either a treatment group or the vehicle control group, the detection call was "marginal" and the -fold change of expression of the corresponding gene was calculated as a provisional value. For example, when the intensity of the gene in a tumor-bearing mouse was "present," but that in a nontumor-bearing mouse was "absent," the ratio of tumor-bearing to nontumor-bearing mouse was calculated using intensity. Data were converted to signal log ratio format using Spotfire Decision Site 8.1.1 (TIBCO Software, Tokyo, Japan). The signal in the treated sample was divided by the corresponding mean value of the vehicle control. When the signal log ratio resulted in a positive value, the -fold change was calculated as the -fold increase (10 (signal log ratio) ). When the signal log ratio resulted in a negative value, the -fold change was calculated as the -fold decrease [Ϫ(10) (Ϫsignal log ratio) ].
To obtain a global view of treatment-related changes in gene expression, cluster analysis was performed on signal log ratios with the cluster package of R (version 2.8.1) using the Pearson correlation distance.
Analysis of Genes Whose Expression Differed between Nontumor-and Tumor-Bearing Mice. To estimate differences in the response between nontumor-and tumor-bearing animals, differential expressed genes were evaluated. The signal log ratios obtained above were analyzed with the treatment comparison function in Spotfire, which calculates p value based on a t test between two groups. After the genes with p Ͻ 0.05 were obtained, common genes among treatments were selected.
Western Immunoblotting. Frozen livers were homogenized with complete lysis M (Roche Diagnostics, Tokyo, Japan) containing 1% Nonidet P-40 using a pestle homogenizer (As One, Osaka, Japan) and centrifuged at 8000g for 1 min. The concentration of protein in the supernatant fractions was measured by a BCA protein assay (Bio-Rad Laboratories, Tokyo, Japan). Protein lysates (2 g/lane) were loaded on 10% SDS-polyacrylamide gels (CosmoBio, Tokyo, Japan), subjected to electrophoresis, and transferred onto Immuno-Blot PVDF membranes (0.2 m; Bio-Rad Laboratories). The PVDF membrane was incubated in a Starting Block (Bio-Rad Laboratories) for 1 h. Primary antibodies (anti-rat CYP1A2, anti-rat CYP2B1, and anti-rat CYP3A2 obtained from Nosan Corporation, Kanagawa, Japan) were diluted 1:5000 with blocking buffer. PVDF membranes were incubated in primary antibody for 1 h at room temperature, after which they were washed 3 times for 5 min in Tris-buffered saline containing 0.05% Tween 20, followed by incubation in the appropriate secondary antibody for 1 h, either goat anti-rabbit IgG-HRP (1:3000 for detection of CYP1A2 and 1:10,000 for CYP3A2; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or donkey anti-goat IgG-HRP (1:10,000 for detection of CYP2B1; Santa Cruz Biotechnology, Inc.). Subsequently, the PVDF membranes were washed 3 times for 5 min, and immunostaining was detected by chemiluminescence with an ECL Plus Western Blotting Detection System (GE Healthcare Bio-Sciences KK, Tokyo, Japan). For detection of ␤-actin, mouse monoclonal ␤-actin-conjugated HRP (Abcam Inc., Cambridge, MA) was incubated for 1 h at a 1:50,000 dilution with blocking reagent after stripping and restaining of the immunoblot. Image capture was performed with an LAS-3000 system (Fujifilm Corporation, Tokyo, Japan), and image analysis was performed with MultiGauge software (Fujifilm Corporation).
Statistical Analysis. Data are expressed as mean Ϯ S.E.M. Statistical analyses were performed with Prism 5.01 (GraphPad Software, Inc., San Diego, CA). ANOVA followed by Tukey's post hoc test was used to compare the data from three or more treatment groups. Student's t test was used for two groups. p Յ 0.05, compared with control, was regarded as statistically significant, which is shown in each figure with an asterisk.
Results
Effect of Tumor Inoculation on Basal Gene Expression in Athymic Mice. The heat map of basal gene expression of ADME-related genes is shown in Fig. 1 , and basal genes whose expression differed between nontumor-and tumor-bearing mice are listed in Table 2 Genes that showed a 2-fold or greater increase in expression after tumor inoculation were Slco1a4 (2.8-fold, p Ͻ 0.001), Cyp4a14 (7.6-fold, p Ͻ 0.01), Cyp2g1 (2.0-fold, p Ͻ 0.05), and Cyp2j9 (2.1-fold, p Ͻ 0.05), and those with a 2-fold or greater decrease were Slc10a2 (0.22-fold, p Ͻ 0.001) and Slc22a7 (0.19-fold, p Ͻ 0.01).
Effect of Tumor Inoculation on the Response to P450 Inducers. Clustering of the samples was performed using results from 105 probe sets after 27 genes were removed because their corresponding mRNAs were undetectable in both vehicle control and treatment groups. These responsive ADME-related gene sets were clustered in two dimensions with respect to the inducing compounds (Fig. 2 , A and B).
Visual inspection of the resulting heat map revealed that typical P450 inducers, MC, PB, and Dex, are clearly separated from each other. In particular, expression of Cyp1a1, Cyp1a2, and Cyp1b1 in the MC treatment group showed clear separation from PB and Dex treatments. The MC treatment group shows mainly two clades of genes with strong up-regulation; the first one is a large clade containing Cyp1a1, Cyp1a2, Cyp1b1, Gstm3, and Gsta1/2, and the second clade is Ugt1a9/10 and Gstp1/2. Although MC and PB treatments were not adjacent to one another, they both caused strong increases in Gsta1/2 and Gstm3, which was not observed after Dex treatment. Cyp2b10, Cyp4a12, and Cyp2d9 comprise a large clade of upregulated genes that do not distinguish PB and Dex treatments. The Within the same treatment group, the samples were clearly separated between nontumor-and tumor-bearing animals. The results suggest that the response to P450 inducers is similar regardless of tumor inoculation, but some differences still exist. Gene sets to identify differences between nontumor-and tumor-bearing mice are described in the following section.
Analysis of Genes Whose Expression Differed between Nontumor-and Tumor-Bearing Mice in Response to P450 Inducers. We used Spotfire to identify genes coregulated by tumor inoculation, setting the level of significance between nontumor-and tumor-bearing mice in each treatment at 5% (i.e., p Ͻ 0.05). We also identified the genes that were specific to inducer treatment if they were significantly different between nontumor-and tumor-bearing mice in each treatment group ( p Ͻ 0.01). Genes whose expression differed between nontumor-and tumor-bearing mice in response to P450 inducers are listed in Table 3 and Supplemental Data 2, respectively, together with the -fold changes in expression of each gene.
The response of ADME genes in each treatment tended to be higher in nontumor-bearing mice compared with tumor-bearing mice (Fig. 3 and Supplemental Data 2). Because the basal expression level of Cyp1a1 is below the detection limit (absent in microarray data) except in MC-treated animals, the -fold change was provisionally calculated using the value below detection limit as the vehicle control value. Genes whose expression differed between nontumor-and tumorbearing mice were not overlapped among treatments except for five genes, but several genes were categorized to same gene family, such as Cyp4a and Cyp4f and Gst and Sult.
The genes that responded differentially between tumor-bearing and nontumor-bearing mice did not include typical inducible genes, such as Cyp1a2 and Cyp1b1 in the MC treatment group or Cyp2b10 and Cyp3a11 in the PB and Dex treatment groups. In other words, the genes induced by standard P450 inducers show similar expression and induction regardless of the presence or absence of the tumor. Genes that showed a different response in tumor-inoculated versus control mice were uptake transporters (Slc family), induced by either Dex or PTX treatments, and the efflux transporters (Abc family), which were induced differently after Dex treatment but not after PTX treatment.
Quantitative Analysis of mRNA (Real-Time RT-PCR) and Protein Expression. Effect of MC treatment on Cyp1a mRNA expression. Because MC is a well-known CYP1A inducer in rodents, we assessed its induction of Cyp1a1 and Cyp1a2 by RT-PCR (Fig. 4A) . MC treatment increased the mRNA levels of Cyp1a1 and Cyp1a2 significantly compared with the vehicle control in both tumor-bearing and nontumor-bearing mice. The basal mRNA levels of Cyp1a1 and Cyp1a2 were not changed by tumor inoculation.
Effect on Cyp2b mRNA expression by PB and Dex treatment. The levels of mRNAs encoding Cyp2b9, Cyp2b10, and Cyp2b13 were assessed after PB treatment (Fig. 4 B) . Cyp2b9 and Cyp2b13 are P450 enzymes predominant in female rodents (Hernandez et al., 2009) .
After PB treatment, Cyp2b10 and Cyp2b13 mRNAs were induced in both tumor-bearing and nontumor-bearing mice, whereas Cyp2b9 mRNA was not affected in either group. Basal Cyp2b10 and Cyp2b13 mRNA expression showed a tendency to increase after tumor inoculation but the increase was not statistically significant. Cyp2b9 mRNA expression was not affected after tumor inoculation.
Effect of Dex and PTX treatments on Cyp3a mRNA expression. The effects of Dex and PTX on Cyp3a mRNA expression are shown in Fig. 4 C. Cyp3a11, Cyp3a41 , and Cyp3a44 were female-predominant P450s (Hernandez et al., 2009) . PTX, an anticancer agent, is known to induce Cyp3a via PXR (Nallani et al., 2003) .
The effects of Dex and PTX treatments on Cyp3a11 and Cyp3a44 mRNA expression were similar between tumor-bearing and nontumor-bearing mice. Dex treatment increased Cyp3a11 and Cyp3a44 mRNA levels and its inductive effect was greater in tumor-bearing mice than in nontumor-bearing mice. PTX treatment increased Cyp3a11, although not statistically significantly but caused no increase in Cyp3a44. On the other hand, Cyp3a41 mRNA expression differed between tumor-bearing mice and nontumor-bearing mice, although this was not statistically significant. That is, Dex and PTX treatments caused a weak increase in expression in tumor-bearing mice but a weak decrease in nontumor-bearing mice. The basal expression levels of Cyp3a11, Cyp3a41, and Cyp3a44 were similar in tumor-bearing and nontumor-bearing mice.
Effect of inducers on nuclear receptor mRNA expression. The effect of typical P450 inducers on nuclear receptor mRNA is shown in Fig.  5 . AhR mRNA levels were increased after MC treatment in both tumor-bearing and nontumor-bearing mice, but the induction was statistically significant only in nontumor-bearing mice (Fig. 5A) . PB treatment caused an increase in CAR mRNA expression in both tumor-bearing and nontumor-bearing mice, but this was statistically significant only in tumor-bearing mice (Fig. 5B) . Dex treatment showed no effect on PXR mRNA levels in either tumor-bearing or nontumor-bearing mice, but PTX treatment increased PXR mRNA in both groups (Fig. 5C ). Basal mRNA expression of AhR, CAR, and PXR was similar between tumor-bearing and nontumor-bearing mice.
Effect of inducers on P450 protein expression. To further characterize the genotypic changes in mouse liver after tumor inoculation, we analyzed the levels of certain P450 enzymes by Western immunoblotting ( Fig. 6 and Supplemental Data 1). Similar to Cyp1a mRNA levels, the levels of Cyp1a protein were dramatically increased in both tumor-bearing and nontumor-bearing mice by MC treatment (Fig.  6A) . The basal protein expression of Cyp1a was increased by tumor inoculation although this increase was not statistically significant.
For Cyp2b, two immunoreactive bands were detected by Western blot analysis. After PB treatment, the lower band increased approximately 2-fold. The upper band was strongly increased by PB treatment, resulting in a 7.6-fold increase in tumor-bearing mice and a 10.2-fold increase in nontumor-bearing mice (Fig. 6B) . The basal protein expression of Cyp2b was significantly increased by tumor inoculation.
Cyp3a protein expression was significantly increased by Dex treatment, whereas PTX had no effect in either tumor-bearing or nontumor-bearing mice (Fig. 6, C and D) . Basal Cyp3a protein expression was increased by tumor inoculation.
Discussion
We present for the first time the effect of tumor inoculation on the expression levels of DMEs and transporters in athymic nude mouse liver. We comprehensively assessed the changes in mRNA levels 
ADME genes that responded differently to inducers between nontumor-and tumor-bearing athymic nude mice
The -fold change was obtained from the signal in the treated sample divided by the mean value of the corresponding control (vehicle), for example, MC treatment in tumor-bearing mice vs. control (vehicle) in tumor-bearing mice and MC treatment in nontumor-bearing mice vs. control (vehicle) in nontumor-bearing mice. The statistical difference of -fold changes between tumor-bearing and nontumor-bearing mice in each treatment was determined by a t test using treatment comparison in Spotfire. ЉPЉ and ЉMЉ in the Flag column indicate ЉpresentЉ and Љmarginal,Љ respectively, as described under Materials and Methods.
Name
RefSeq Identification Flag ADME gene set responds to more than three compounds:
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at ASPET Journals on April 19, 2017 dmd.aspetjournals.org caused by tumor inoculation, including the basal mRNA expression levels and response to typical P450 inducers of DME, transporters, and nuclear receptors using a focused gene microarray. These results were then analyzed further by RT-PCR and Western immunoblotting. Effect of Tumor Inoculation on ADME Gene Induction. Clustering of microarray data showed a clear separation of gene expression patterns by compound treatment. It is interesting to note that within each treatment group, gene expression clusters were separated between nontumor-bearing and tumor-bearing mice (Fig. 2, A and B) . Furthermore, most of genes whose expression differed between tumor-bearing and nontumor-bearing mice showed higher -fold induction in nontumor-bearing mice (Fig. 3 ), but these differentiated gene sets did not include typical inductive target genes, such as Cyp1a2 induced by MC, Cyp2b10 induced by PB, and Cyp3a11 induced by Dex (Table 3) . These results indicate that any induction of P450 genes by new chemical entities should be expected to be similar between tumor-bearing and control mice. However, tumor inoculation does affect other genes. Genes whose expression differed between tumorbearing and nontumor-bearing mice in each treatment included the Cyp4, Gst, Sult, and Slc transporters, which would cause minor changes in drug metabolism. The Cyp4 family includes Cyp4a and Cyp4f and is involved in fatty acid -hydroxylation in liver and kidney (Simpson, 1997; Muller et al., 2007) . Gst and Sult are both involved in phase II conjugation with glutathione and sulfonation, respectively, of xenobiotics, endogenous neurotransmitters, and hormones. Because many antitumor drugs have been detected to be metabolized more extensively by the CYP1, 2, or 3 families of isozymes (MacLeod et al., 2000; Harmsen et al., 2007) , we would expect little, if any, effect of Cyp4, Gst, and Sult on drug metabolism.
The mRNA levels of AhR and CAR were increased by MC and PB treatment, respectively (Fig. 5) , consistent with the notion that Cyp1a1/2 and Cyp2b10 mRNA expression is dependent on the transcription factors, AhR and CAR, respectively. PXR mRNA levels were not affected by Dex treatment but were increased by PTX treatment. Thus, Cyp3a11 mRNA and Cyp3a protein expression showed a pattern opposite to that of PXR mRNA expression, indicating that the observed increase in Cyp3a11 mRNA was not PXRdependent in this study. Regarding PTX treatment, we did not observe clear induction of Cyp3a11 mRNA, as has been reported (Nallani et al., 2003) . This might be due to differences in the animal strain, sex, and/or solvent component. Because Dex is a potent synthetic glucocorticoid, CYP3A induction by Dex treatment is thought to involve at least two receptors: the glucocorticoid receptors and PXR. Although PXR and Cyp3a11 mRNAs showed similar expression patterns (Down et al., 2007) , Cyp3a11 induction by Dex was observed in both PXR knockout and wild-type mice (Zimmermann et al., 2009 ), indicating that Cyp3a11 induction is mediated at least via glucocorticoid receptors. The involvement of other transcription factors and posttranslational regulation in the regulation of P450 genes has been reported (Zordoky and El-Kadi, 2009 ). Solvents such as ethylbenzene and dimethyl sulfoxide increase CYP3A protein and catalytic activity but do not alter CYP3A mRNA levels (Yuan et al., 1994; Zangar et al., 1997) . Down-regulation of CYP3A4 mRNA expression in human primary hepatocytes was not associated with changes in steroid X receptor mRNA, a human ortholog of PXR (Zhou et al., 2006) . The mechanism of Cyp3a induction needs to be further investigated.
Effect of Tumor Inoculation on Basal ADME Gene Expression. Basal ADME gene expression was affected by tumor inoculation. Most of the genes studied on microarray, especially the Cyp family, were increased by tumor inoculation, and their increase was less than 2-fold ( Fig. 1; Table 2 ). However, some remarkable changes were observed in a few instances. For example, Slc22a7 mRNA expression FIG. 3 . ADME genes that responded differently to inducers between nontumor-and tumor-bearing athymic nude mice. The -fold change compared with corresponding vehicle control in each treatment was statistically different between tumor-bearing and nontumor-bearing mice (p Ͻ 0.05).
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at ASPET Journals on April 19, 2017 dmd.aspetjournals.org was decreased and that of Cyp4a14 was increased by tumor inoculation. Slc22a7 is a well known organic anion transporter 2 that has important roles in the transport of endogenous compounds, such as propionate, a potent gluconeogenic compound (Islam et al., 2008) , as well as cytostatic drugs such as 5-fluorouracil, methotrexate, and paclitaxel (Taxol) (Rizwan and Burckhardt, 2007) . Thus, the suppression of Slc22a7 in host liver by tumor inoculation may have a large impact on the PK profile of xenobiotics when they are the substrates for organic anion transporter 2.
With use of RT-PCR, the basal expression levels of major DMEs were found to be similar between tumor-bearing and nontumorbearing mice (Fig. 4) . It is interesting to note that Western immunoblotting revealed that basal protein levels for Cyp1a, Cyp2b, and Cyp3a were decreased by tumor inoculation, even though we observed no change in the basal mRNA levels of the nuclear receptors that regulate their expression, namely AhR, CAR, and PXR. The reason for this is unclear, but tumor inoculation may cause a change in post-translational regulation, such as enhanced protein turnover or lowered translational efficiency of mRNA. Lee et al. (2009) reported that CYP3A was post-transcriptionally down-regulated by cytokine in rat hepatocytes. In addition, the nuclear factor B pathway is reported to regulate the stability of CYP3A4 protein: inhibition of nuclear factor-B increased CYP3A4 mRNA but suppressed the CYP3A4 protein level (Zangar et al., 2008) . Because P450 is involved in the metabolism of many antitumor drugs (Harmsen et al., 2007) , the change in basal P450 protein levels by tumor inoculation should have a large impact on the PK profile of xenobiotics, thereby resulting in different PK profiles between normal mice and tumor-bearing mice.
It is well recognized that some tumors can secrete hormonal substances, many of which are peptide hormones, that can enter into the systemic circulation and affect the normal tissues of host animals. For instance, angiogenic cytokine production from tumors including basic fibroblast growth factor, vascular endothelial growth factor, and tumor necrosis factor-␣ has been reported to be dependent not only on inoculation site (Keyes et al., 2003b) but also on the species of tumor cells inoculated (Keyes et al., 2003a) . Furthermore, these angiogenic cytokines have been detected in host plasma, indicating that they can circulate throughout the host body and could affect gene regulation in the liver. It has also been suggested that inoculation of different tumor cell lines could have different effects on ADME-related proteins. A   FIG. 4 . The effect of inducers on liver Cyp1a (A), Cyp2b (B), and Cyp3a (C) mRNA expression in nontumor-and tumor-bearing athymic nude mice. mRNA expression was assessed by real-time PCR as described under Materials and Methods. On the y-axis, the -fold change is shown compared with vehicle control (Cont) of tumor-bearing mouse liver. For the vehicle controls in tumor-bearing mouse liver, the mean value was used for calculations. Data are expressed as mean Ϯ S.E.M. (vehicle control n ϭ 3 and treatment n ϭ 4) for each of the different P450 enzymes in tumor-bearing mice and nontumor-bearing mice. f, tumor-bearing mice; Ⅺ, nontumor-bearing mice. ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001, compared with corresponding vehicle control (one-way ANOVA followed by Tukey's test as the post hoc test for more than three individuals, unpaired two-tailed t test for two individuals). The basal mRNA levels in vehicle control were not statistically significant between tumor-bearing and nontumor-bearing mice in all genes examined (unpaired two-tailed t test).
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at ASPET Journals on April 19, 2017 dmd.aspetjournals.org change in antioxidant blood status was observed in subcutaneously inoculated xenograft mice harboring bladder tumors (Gauchez et al., 1995) , indicating that tumor tissue itself could induce oxidative stress into its host. On the other hand, the enzyme activities and the expression of many P450s are down-regulated during inflammation and infection, which can arise from cancer, causing decreased metabolic clearance of P450 substrates and increased plasma drug levels (Charles et al., 2006; Sharma et al., 2008) . Sharma et al. (2008) used C57BL/6 mice that had been subcutaneously inoculated with B16 melanoma or E0771 breast cancer cells, both of which originated from mouse,. In contrast, the xenograft models typically used in oncology research consist of nude mice inoculated with human cancer cells. Although T-cell deficiency and metastasis rarely occur in subcutaneous xenografts, cytokines produced by tumors inoculated into athymic mice circulate through the host body and could possibly affect regulation of DMEs in host liver. The decrease in the expression of these P450 proteins by tumor inoculation would reduce metabolic function, which may change the PK profile between tumor-bearing mice and nontumor-bearing mice.
Tumor-host interactions were reported to alter the PK of alkylating agents. According to Teicher et al. (1990) , platinum and cyclophosphamide were absorbed and distributed similarly in the livers of tumor-bearing and control mice; however, elimination was much more rapid in nontumor-bearing mice than in tumor-bearing mice. In their study, they reported that very high levels of resistance to anticancer drugs that developed in vivo altered the PK profile between nontumor-bearing mice and tumor-bearing mice; however, they did not describe any changes in DMEs. Because these alkylating agents are known to be substrates for CYP3A4/5 in humans (Harmsen et al., 2007) and there is a good correlation between immunoreactive protein and substrate for human liver (Löfgren et al., 2004) , suppression of Cyp3a could also contribute to an area under the curve increase in the liver or kidney in tumor-bearing animals.
In conclusion, tumor inoculation was shown to have significant effects on the basal expression levels of some of the ADME-related genes. In our analyses of the P450s, tumor inoculation decreased basal protein expression but not mRNA expression of Cyp1a, Cyp2b, and Cyp3a, suggesting that drug metabolism may be suppressed by tumor inoculation. These results indicated that there could be significant differences in drug PK profiles in tumorbearing mice versus nontumor-bearing mice. In addition, the effect on ADME-related proteins could be different depending on the tumor cell line inoculated, which makes PK/PD analysis difficult when normal mice are used for PK analysis. The correlation between PK and PD of antitumor drugs in animal studies is very important for clinical development of the drug being examined. Therefore, it may be prudent to assess the exposure of new chemical entities using the same tumor-bearing model as in the phar- FIG. 5 . Liver AhR (A), CAR (B), and PXR (C) mRNA expression in tumor-bearing and nontumor-bearing mice. mRNA expression was assessed by real-time PCR as described under Materials and Methods. On the y-axis, -fold change after treatment is shown compared with the vehicle control (Cont) of tumor-bearing mouse liver. For the vehicle controls in tumor-bearing mouse liver, the mean value was used for calculations. Data are expressed as mean Ϯ S.E.M. (control n ϭ 3 and treatment n ϭ 4) for each of the different P450s in tumor-bearing and nontumor-bearing mice. f, tumor-bearing mice; Ⅺ, nontumor-bearing mice. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001, compared with the corresponding vehicle control (one-way ANOVA followed by Tukey's test as the post hoc test) for more than three individual animals or unpaired two-tailed t test for two individual animals). The basal mRNA levels in vehicle control were not statistically significant between tumor-bearing and nontumor-bearing mice in all genes examined (unpaired two-tailed t test). The -fold change was obtained from the signal in the treated sample divided by the mean value of the corresponding control (vehicle), for example MC treatment in tumor-bearing mice vs. control (vehicle) in tumor-bearing mice and MC treatment in non-tumor mice vs. control (vehicle) in non-tumor mice. The statistical difference of -fold changes between tumor-bearing and non-tumor mice in each treatment was determined by t-test using treatment comparison in Spotfire. "P" and "M" in Flag indicate "present" and "marginal", respectively, as described in Material and Method.
